Key result
In silico analysis categorizes four CYP2C19 variants into phenotypes predicting clopidogrel metabolism and safety.
Why the study?
To predict the functional impact of four CYP2C19 genetic variants on drug metabolism to improve personalized medicine and safety for drugs like Clopidogrel.
Does in silico analysis of CYP2C19 genetic variants predict their functional impact on the metabolism of drugs like clopidogrel?
Does in silico analysis of CYP2C19 genetic variants predict their functional impact on the metabolism of drugs like clopidogrel?
In silico analysis of CYP2C19 variants can predict metabolic phenotypes, potentially improving personalized medicine and safety for drugs like clopidogrel.
May facilitate personalized clopidogrel therapy via CYP2C19 phenotyping; extends in silico predictions but requires clinical validation before adoption.
This study provides an in silico analysis of four CYP2C19 genetic variants—rs3758581, rs113994117, rs12248560, and rs28399504—to predict their functional impact on drug metabolism. Using SIFT and PolyPhen-2, the research categorizes these mutations into metabolic phenotypes to improve personalized medicine and safety for drugs like Clopidogrel.
No takes yet. Share an insight, caveat, or question.
Aakriti Kaushal (2026) studied this question. In silico analysis of four CYP2C19 genetic variants categorized them into metabolic phenotypes to predict their impact on the metabolism and safety of drugs like Clopidogrel.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: